PHACTR1

PHACTR1 rs9349379 — The Vascular Switcher: Migraine Risk Versus Heart-Attack Protection

A single nucleotide variant sitting in an intron of the PHACTR1 gene on chromosome 6
has one of the most remarkable genetic profiles in cardiovascular and neurological
medicine: its two alleles pull risk in opposite directions across five vascular
diseases. Carry the A allele and you are predisposed to migraine headaches, cervical
artery dissection, and fibromuscular dysplasia. Carry the G allele and your migraine
risk falls — but your risk of coronary artery disease and myocardial infarction rises.
The same switch, flipped in opposite directions for two different arteries, illustrates
why the PHACTR1 locus has attracted intense interest from both neurologists and
cardiologists.

PHACTR1 | phosphatase and actin regulator 1 — a protein involved in cytoskeletal
regulation, vascular compliance, and endothelial gene expression
is expressed predominantly in endothelial and vascular smooth muscle cells. The
rs9349379 variant lies in a large intron (between exons 5 and 6) but is not silent —
it sits in a regulatory enhancer active in aortic tissue and alters the binding of
myocyte enhancer factor-2 (MEF2) transcription factors to that enhancer.

The Mechanism

The molecular story has two layers. First, rs9349379 affects PHACTR1's own expression:
the G allele disrupts MEF2 binding, reducing PHACTR1 transcription in human coronary
arteries and aorta. Wang & Musunuru 2018 | Circulation Genomic Precision Med
confirmed this using CRISPR-edited iPSC-derived endothelial cells with knock-in of
each allele — GG homozygotes expressed less PHACTR1 than AA homozygotes.

Second, and more dramatically, rs9349379 acts as a distal enhancer for endothelin-1
(EDN1), located 600 kb upstream of PHACTR1. Gupta et al. 2017 | Cell
used CRISPR deletion of the 88-bp regulatory element at rs9349379 in iPSC-derived
endothelial cells and vascular smooth muscle cells; deletion increased EDN1 expression,
and analysis of 99 healthy individuals confirmed that each G allele raises Big ET-1
plasma levels. Endothelin-1 is a potent vasoconstrictor that also promotes vascular
smooth muscle proliferation, extracellular matrix deposition, and arterial fibrosis
— effects consistent with coronary plaque vulnerability.

The opposing disease profiles arise because atherosclerotic coronary artery disease
(plaque-dependent) and migraine with aura (vasospasm and cortical spreading depression)
represent fundamentally different vascular failure modes. Higher ET-1 from the G allele
promotes the chronic endothelial injury model of atherosclerosis while the A allele's
arterial-wall compliance changes (fibromuscular dysplasia, CeAD) reflect a structural
fragility model distinct from plaque. PHACTR1 itself, when reduced by the G allele,
may also modulate endothelial inflammation via NF-κB-dependent ICAM-1/VCAM-1 expression.

The Evidence

Hautakangas et al. 2022 | Nature Genetics
— the largest migraine GWAS to date (102,084 cases, 771,257 controls) — identified
rs9349379 as the sole credible causal variant at the PHACTR1 locus with a posterior
inclusion probability of 1.00. The association reached P ≈ 1×10⁻⁴⁷, placing it
among the top migraine loci genome-wide. PHACTR1 was one of only two genes
prioritized with strong evidence by both gene prioritization methods used in the
study. The association held for migraine both with and without aura.

The pleiotropy was formally quantified by Winsvold et al. 2017 | PLOS ONE
using conjunctional FDR analysis across 23,285 migraine cases and multiple CAD
cohorts: the A allele showed beta = +0.073 for migraine (P = 6.4×10⁻⁸) but
beta = −0.159 for CAD (P = 6.5×10⁻²¹) — opposite signs, both highly significant.

For cervical artery dissection, Debette et al. 2015 | Nature Genetics
found the G allele protective (OR = 0.75, P = 4.5×10⁻¹⁰, 2,052 cases/17,064
controls). For fibromuscular dysplasia, Kiando et al. 2016 | PLoS Genetics
found the A allele confers OR = 1.39 (P = 7.4×10⁻¹⁰, 1,154 FMD cases). The A
allele is rare in Africans (~8%) but common in East Asians (~32% homozygous AA),
producing dramatically different population-level vascular disease burdens.

Practical Actions

For carriers of the AA genotype (two A alleles): migraine susceptibility is elevated,
and while the vascular mechanism is distinct from classical atherosclerosis, the
endothelial and arterial-wall changes associated with the A allele also raise risk
of cervical artery dissection and fibromuscular dysplasia. Vasoconstrictive migraine
treatments (ergotamine, dihydroergotamine) carry theoretical concern in individuals
already predisposed to arterial wall pathology, and triptans — which carry black-box
warnings for coronary vasospasm — are worth discussing with a neurologist who knows
this genotype.

For GG carriers: migraine risk is low, but the G allele's higher ET-1 production
and reduced PHACTR1 expression increase coronary artery disease risk independently
of traditional risk factors. Standard cardiovascular risk management is therefore
especially important.

Interactions

The PHACTR1 locus interacts at the pathway level with other vascular endothelial
variants. The EDN1 pathway is shared with rs5370 (EDN1 Lys198Asn), which directly
alters the endothelin-1 peptide sequence and affects vasoconstrictor tone. Variants
in EDNRA and EDNRB (endothelin receptor genes) could compound the rs9349379 regulatory
effect on ET-1 signalling. NOS3 variants (e.g., rs1799983 ENOS Glu298Asp) affecting
nitric oxide production operate antagonistically to endothelin-1 in vascular tone
regulation; a combined PHACTR1-AA / NOS3-risk genotype may produce additive vascular
wall dysfunction. These pathway interactions are candidates for compound actions but
require published evidence of combined effects before they can be formally modelled.